Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.35 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795889 | 0.84 | CYP19A1 (0.35) | MMP2MEN1KMT2A | |
| SCHEMBL6701363 | 0.84 | MMP2 (0.31) | MMP2 | |
| Ammonia Solution, Strong SCHEMBL6793015 | 0.83 | CYP19A1 (0.34) | MMP2MEN1KMT2A | |
| SCHEMBL6789361 | 0.81 | MMP2 (0.41) | MMP2AKR1B1 | |
| SCHEMBL6791153 | 0.81 | MMP2 (0.41) | MMP2AKR1B1 | |
| SCHEMBL6791227 | 0.81 | MMP2 (0.41) | MMP2AKR1B1 | |
| SCHEMBL6794498 | 0.80 | MMP8 (0.45) | CYP1A2AKR1B1MEN1KMT2A | |
| SCHEMBL6795148 | 0.80 | AKR1B1 (0.35) | HSD11B1ADAMTS5AKR1B1AKR1A1 | |
| SCHEMBL6790620 | 0.80 | MMP2 (0.43) | HSD11B1MMP2MMP13ADAMTS5AKR1B1 | |
| SCHEMBL6798425 | 0.79 | CYP17A1 (0.37) | MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040116486-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370535-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074749-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | HSD11B1 64/4885MMP2 11/4885MMP13 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.